1. Home
  2. MCI vs ELDN Comparison

MCI vs ELDN Comparison

Compare MCI & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barings Corporate Investors

MCI

Barings Corporate Investors

HOLD

Current Price

$17.72

Market Cap

364.9M

Sector

Finance

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$3.74

Market Cap

300.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCI
ELDN
Founded
1971
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
364.9M
300.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MCI
ELDN
Price
$17.72
$3.74
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
35.0K
1.3M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
8.46%
N/A
EPS Growth
N/A
30.67
EPS
1.82
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.57
$1.35
52 Week High
$23.00
$4.60

Technical Indicators

Market Signals
Indicator
MCI
ELDN
Relative Strength Index (RSI) 52.18 55.41
Support Level $17.27 $3.35
Resistance Level $18.08 $4.09
Average True Range (ATR) 0.37 0.32
MACD 0.02 0.03
Stochastic Oscillator 70.00 44.60

Price Performance

Historical Comparison
MCI
ELDN

About MCI Barings Corporate Investors

Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Share on Social Networks: